BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24498956)

  • 1. Novel glycobiomarker for ovarian cancer that detects clear cell carcinoma.
    Sogabe M; Nozaki H; Tanaka N; Kubota T; Kaji H; Kuno A; Togayachi A; Gotoh M; Nakanishi H; Nakanishi T; Mikami M; Suzuki N; Kiguchi K; Ikehara Y; Narimatsu H
    J Proteome Res; 2014 Mar; 13(3):1624-35. PubMed ID: 24498956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.
    Arakawa N; Kobayashi H; Yonemoto N; Masuishi Y; Ino Y; Shigetomi H; Furukawa N; Ohtake N; Miyagi Y; Hirahara F; Hirano H; Miyagi E
    PLoS One; 2016; 11(10):e0165609. PubMed ID: 27798689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of a glycoproteomics-based biomarker development method: alteration in glycan structure on colony stimulating factor 1 receptor as a possible glycobiomarker candidate for evaluation of liver cirrhosis.
    Ocho M; Togayachi A; Iio E; Kaji H; Kuno A; Sogabe M; Korenaga M; Gotoh M; Tanaka Y; Ikehara Y; Mizokami M; Narimatsu H
    J Proteome Res; 2014 Mar; 13(3):1428-37. PubMed ID: 24422531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoproteomic Analysis of Malignant Ovarian Cancer Ascites Fluid Identifies Unusual Glycopeptides.
    Miyamoto S; Ruhaak LR; Stroble C; Salemi MR; Phinney B; Lebrilla CB; Leiserowitz GS
    J Proteome Res; 2016 Sep; 15(9):3358-76. PubMed ID: 27500424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large-scale identification of secretome glycoproteins recognized by Wisteria floribunda agglutinin: A glycoproteomic approach to biomarker discovery.
    Sugahara D; Tomioka A; Sato T; Narimatsu H; Kaji H
    Proteomics; 2015 Sep; 15(17):2921-33. PubMed ID: 25921242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients.
    Dalal V; Kumar R; Kumar S; Sharma A; Kumar L; Sharma JB; Roy KK; Singh N; Vanamail P
    Clin Chim Acta; 2018 Jul; 482():27-32. PubMed ID: 29572186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum glycome profiling: a biomarker for diagnosis of ovarian cancer.
    Biskup K; Braicu EI; Sehouli J; Fotopoulou C; Tauber R; Berger M; Blanchard V
    J Proteome Res; 2013 Sep; 12(9):4056-63. PubMed ID: 23889230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secretome-based identification of TFPI2, a novel serum biomarker for detection of ovarian clear cell adenocarcinoma.
    Arakawa N; Miyagi E; Nomura A; Morita E; Ino Y; Ohtake N; Miyagi Y; Hirahara F; Hirano H
    J Proteome Res; 2013 Oct; 12(10):4340-50. PubMed ID: 23805888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources.
    Gidwani K; Huhtinen K; Kekki H; van Vliet S; Hynninen J; Koivuviita N; Perheentupa A; Poutanen M; Auranen A; Grenman S; Lamminmäki U; Carpen O; van Kooyk Y; Pettersson K
    Clin Chem; 2016 Oct; 62(10):1390-400. PubMed ID: 27540033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
    Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
    Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ascites N-glycome of epithelial ovarian cancer patients.
    Biskup K; Braicu EI; Sehouli J; Tauber R; Blanchard V
    J Proteomics; 2017 Mar; 157():33-39. PubMed ID: 28188862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma.
    Takaya A; Peng WX; Ishino K; Kudo M; Yamamoto T; Wada R; Takeshita T; Naito Z
    Int J Oncol; 2015 Apr; 46(4):1573-81. PubMed ID: 25633807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycoproteomic identification of potential glycoprotein biomarkers in ovarian cancer proximal fluids.
    Kuzmanov U; Musrap N; Kosanam H; Smith CR; Batruch I; Dimitromanolakis A; Diamandis EP
    Clin Chem Lab Med; 2013 Jul; 51(7):1467-76. PubMed ID: 23241603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
    Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
    Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of oncofetal fibronectin in patients with advanced epithelial ovarian cancer: detection in ascitic fluid and localization to primary sites and metastatic implants.
    Menzin AW; Loret de Mola JR; Bilker WB; Wheeler JE; Rubin SC; Feinberg RF
    Cancer; 1998 Jan; 82(1):152-8. PubMed ID: 9428492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The application value of the detection of the level of tissue polypeptide antigen, ovarian cancer antigen X1, cathepsin L and CA125 on the diagnosis of epithelial ovarian cancer.
    Lv XL; Zhu Y; Liu JW; Ai H
    Eur Rev Med Pharmacol Sci; 2016 Dec; 20(24):5113-5116. PubMed ID: 28051260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a multi-marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women.
    Zhang P; Wang C; Cheng L; Zhang P; Guo L; Liu W; Zhang Z; Huang Y; Ou Q; Wen X; Tian Y
    Tumour Biol; 2016 Feb; 37(2):2183-91. PubMed ID: 26349751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum 27-nor-5β-cholestane-3,7,12,24,25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer.
    Chen J; Zhang X; Cao R; Lu X; Zhao S; Fekete A; Huang Q; Schmitt-Kopplin P; Wang Y; Xu Z; Wan X; Wu X; Zhao N; Xu C; Xu G
    J Proteome Res; 2011 May; 10(5):2625-32. PubMed ID: 21456628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.